CD19 and acute lymphoblastic leukemia: In a study conducted at the Fred Hutchinson Cancer Research Center in Seattle, a total of 32 patients (ALL, n = 19; NHL/CLL, n = 13) underwent allo-HCT after ≥1 CD19-targeted CAR-T infusions with a defined CD4:CD8 ratio (36).